Opara: biotech market needs education
05 September, 2005 by Ruth BeranDr Richard Opara, a substantial shareholder in biotech companies Polartechnics (ASX:PLT) and Avantogen (ASX:ACU), is trying to raise money for a new start-up capital biotech fund, but is finding the going tough in Australia and may have to go overseas to find the cash.
Clinical Cell Culture posts record revenues
02 September, 2005 by Ruth BeranTissue-engineering biomedical company Clinical Cell Culture (ASX:CCE, C3) has posted record revenues of AUD$1.4 million, up 51 per cent in the 18 month period from January 1, 2004 to June 30, 2005 (2003: $0.95 million).
Norwood raises US$10m from US investors
02 September, 2005 by Helen SchullerNorwood Abbey (ASX:NAL) has raised AUD$13.3 million (US$10 million) through US institutional investors to make the final payment on its products used in vision correction surgery and to expand production.
HeartWare implants first mini heart device
01 September, 2005 by Helen SchullerUS artificial heart firm HeartWare (ASX:HTW) has successfully commenced its animal studies by implanting its Miniaturised Ventricular Assist Device (MVAD) in a calf.
Pharmaxis boosted by cystic fibrosis study
31 August, 2005 by Helen SchullerPharmaxis' (ASX:PXS) drug Bronchitol has produced positive results from a phase II trial in cystic fibrosis patients, described by CEO Alan Robertson as "a landmark study and transforming day for Pharmaxis and the cystic fibrosis community".
Phylogica teams with Fox Chase
31 August, 2005 by Graeme O'NeillPhylogica (ASX:PYC) has signed a partnership with leading US cancer research institute, the Fox Chase Centre, that gives the Perth peptide therapeutics developer an exclusive global licence to exploit Fox Chase's proprietary technology to screen molecules for anti-cancer activity.
Antisense set to restart MS drug trial
31 August, 2005 by Helen SchullerMelbourne's Antisense Therapeutics (ASX:ANP) is planning to restart the phase IIa trial of its lead drug candidate for multiple sclerosis ATL1102 before the end of the year, following recommendations from its advisory board.
Novogen posts increased revenue
31 August, 2005 by Ruth BeranPharmaceutical company Novogen (ASX:NRT) saw revenues of AUD$17.7 million for 2004-05, a 7.5 per cent increase on the previous year, and a net loss of $11.1 million.
New research facilities open in WA, Qld
31 August, 2005 by Staff WritersTwo new research facilities have opened their doors, one a joint venture between the University of Western Australia (UWA) and the Western Australian Institute for Medical Research (WAIMR), and the other based at the University of Queensland's Institute for Molecular Bioscience (IMB).
ZingoTX nets $1.45m fed grant
30 August, 2005 by Helen SchullerPain management company ZingoTX, a subsidiary of Eqitx (ASX:EQX) has been awarded a AUD$1.45 million AusIndustry Commercial Ready grant to support the ZingoTX drug development program over the next 12 months.
Neuren initiates phase II trial
30 August, 2005 by Helen SchullerAuckland biopharma Neuren Pharmaceuticals (ASX: NEU) has begun to recruit the 30 patients who will take part in its phase II pharmacokinetics and safety trial of its lead drug Glypromate.
Metabolic records 'straightforward' result
29 August, 2005 by Helen SchullerMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has reported a loss of AUD$10.7 million for the year ended 30 June 2005, up 13 per cent from $9.5 million last year.
SciGen revenues, loss up
29 August, 2005 by Ruth BeranSingapore-based generics company SciGen (ASX:SIE) has posted a net loss of SGD$5.6 million (AUD$4.43 million) for 2004-05, up 29 per cent from the previous financial year.
Orchestrating serendipity
29 August, 2005 by Ann UldridgeAnn Uldridge explains the reasoning behind a new group for women in the biotechnology industry.
NeuroSolutions appoints Sigma Aldrich for scale-up
26 August, 2005 by Helen SchullerNeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year.
